Applications of (S)-4-(4'-Nitrobenzyl)-1,3-Oxazolidine-2-One in Industrial Manufacturing

(S)-4-(4'-Nitrobenzyl)-1,3-Oxazolidine-2-One serves as a specialized chiral intermediate for several high-value industrial synthesis tracks. Our manufacturing expertise enables precise control over purity and reproducibility, supporting critical applications in pharmaceutical and fine chemical fields. Below, we detail its targeted use in distinct downstream manufacturing routes.

1. Chiral Synthesis for Active Pharmaceutical Ingredients (APIs)

Pharmaceutical manufacturers utilize this compound as a key building block for stereoselective API synthesis, especially where precise enantiomeric purity is essential. It enters multistep reaction schemes, acting as a chiral auxiliary or precursor for beta-lactam derivatives, antivirals, and certain neurologically active compounds. Each stage requires strict adherence to process analytical control and batch consistency to meet regulatory review for new drug submissions.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• 21 CFR Part 210/211 (US FDA)
• EU EudraLex Volume 4 GMP
• Japanese Pharmacopoeia (JP)

Typical usage ratio

• 0.7–1.3 molar equivalent relative to target chiral center; adjusted per enantiomeric excess targets and downstream intermediate conversion yield

Downstream process integration

• Introduced during stereospecific alkylation/acylation or resolution stages, then removed or transformed in subsequent hydrolysis or ring-opening steps prior to final API coupling

Final product types

• Beta-lactam antibiotic APIs
• Non-sedative antihistamine intermediates
• Chiral antivirals
• Neurological active pharmaceutical ingredients

2. Fine Chemical Intermediates for Asymmetric Catalysis

Chemical manufacturers employ this compound as a source of chiral induction in the synthesis of ligands and catalyst precursors for asymmetric hydrogenation and cyclization reactions. Its structural properties allow the controlled introduction of stereochemistry into fine chemical intermediates, essential for producing optically active specialty molecules. Strict management of trace-level impurities ensures reliable catalyst performance and batch reproducibility for commercial synthesis operations.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• REACH (EU Regulation on Registration, Evaluation, Authorisation and Restriction of Chemicals)
• ACS Reagent Grade specifications for trace analysis

Typical usage ratio

• 0.2–1.0 equivalents relative to transition metal content or substrate; adjusted according to conversion efficiency and optical yields in pilot-scale trials

Downstream process integration

• Added at catalyst ligand formation or as a chiral directing group pre-catalysis; removed by reductive cleavage, hydrolysis, or chromatography after product generation

Final product types

• Chiral phosphine ligands
• Asymmetric hydrogenation catalysts
• Specialty amine intermediates
• High-value optical isomers

3. Synthesis of Specialty Agrochemical Intermediates

In agrochemical manufacturing, formulators select this material as a chiral intermediate to construct specific enantiopure segments of fungicides and herbicides. Its performance during enantioselective synthesis directly affects downstream biological activity and registration process outcomes. Process engineers control batch input and monitor for regulated impurities, supporting compliance with international agrochemical quality protocols and minimizing off-target activity in final formulations.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• FAO Specifications for Plant Protection Products
• ISO 17025:2017 Testing Laboratories
• China GB/T 1605-2001 for agrochemical intermediates

Typical usage ratio

• 0.5–1.1 molar equivalents per target chiral agrochemical precursor; determined by desired enantiomeric excess and yield in downstream reactions

Downstream process integration

• Incorporated at the key chiral center construction step, followed by functional group adjustment and purification ahead of formulation blending

Final product types

• Chiral herbicide intermediates
• Enantiopure fungicide actives
• Precursor blocks for insecticidal compounds
• Custom agricultural active ingredients

4. Peptide Drug Intermediate Production

Peptide drug producers utilize this compound in the synthesis of optically active amino acid derivatives and unnatural building blocks. Its capability for stereoselective transformation under mild conditions is critical for protecting group strategies and segment coupling steps in peptide elongation. Our technical support ensures consistent input quality and facilitates compliance with international peptide GMP requirements, affecting both process scalability and finished drug purity profiles.

Industry compliance standards

• US Pharmacopeia (USP) standards for peptide synthesis
• EMA GMP for Peptides and Recombinant Products
• ICH Q11 Development and Manufacture of Drug Substances
• ISO 13408-1 for aseptic processing

Typical usage ratio

• 0.9–1.2 equivalents per peptide coupling cycle; adjusted to block racemization or fine-tune stepwise purity, subject to validation in development

Downstream process integration

• Employed at sidechain protection or N-terminal modification, then cleaved prior to final cyclization or during global deprotection phase

Final product types

• Peptide hormone intermediates
• Custom amino acid derivatives
• Cyclic peptide lead compounds
• API-grade synthetic peptides